Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Taysha Gene Therapies (TSHA) Leases (2022 - 2025)

Taysha Gene Therapies' Leases history spans 4 years, with the latest figure at $7.5 million for Q3 2025.

  • For Q3 2025, Leases fell 14.0% year-over-year to $7.5 million; the TTM value through Sep 2025 reached $7.5 million, down 14.0%, while the annual FY2024 figure was $8.4 million, 12.53% down from the prior year.
  • Leases for Q3 2025 was $7.5 million at Taysha Gene Therapies, down from $7.8 million in the prior quarter.
  • Across five years, Leases topped out at $10.9 million in Q4 2022 and bottomed at $7.5 million in Q3 2025.
  • The 4-year median for Leases is $9.1 million (2024), against an average of $9.2 million.
  • The largest annual shift saw Leases fell 11.92% in 2024 before it dropped 14.0% in 2025.
  • A 4-year view of Leases shows it stood at $10.9 million in 2022, then dropped by 12.44% to $9.6 million in 2023, then fell by 12.53% to $8.4 million in 2024, then decreased by 10.95% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Leases are $7.5 million (Q3 2025), $7.8 million (Q2 2025), and $8.1 million (Q1 2025).